genome, and mutations in some of these genes have been implicated in human hereditary diseases such as X-linked Charcot-Marie-Tooth disease, sensorineural hearing loss, oculodentodigital dysplasia, cataracts, and idiopathic atrial fibrillation. 2 The present study focuses on connexin 37 (Cx37), an isoform expressed in endothelial cells (ECs), vascular smooth muscle cells, monocytes, and macrophages. 3 Studies on genetically modified mouse models showed the involvement of Cx37 in the pathogenesis of atherosclerosis. 4, 5 Studies in humans indicate that a polymorphism at position 1019 of the GJA4 gene, encoding for human Cx37, may be a prognostic marker for atherosclerosis (reviewed in Reference 3). This C1019T polymorphism codes for a proline-to-serine substitution (P319S) in the C-terminal domain of the protein. Two separate studies showed a correlation between the presence of the Cx37-319S isoform and an increased prevalence of myocardial infarction in the sampled population. 6, 7 The Cx37-319S genotype was also shown to predict survival after an acute coronary syndrome. 8 In 3 additional studies, the alternative isoform (Cx37-319P) was associated with an increased prevalence of stenosis in the coronary 9, 10 or the carotid arteries. 11 Studies at the cellular level recently showed that Cx37 expression inhibited monocyte adhesion to the endothelium; this effect was more pronounced in monocytes expressing Cx37-319P than in those expressing Cx37-319S. 5 In this study, we demonstrate that megakaryocytes and platelets express Cx37 and that Cx37 plays a crucial role in the physiological and pathological signaling in platelets leading to hemostasis and thrombosis. We found that gap junctional intercellular communication (GJIC) between aggregating platelets limits thrombus propensity by downregulating platelet reactivity. In addition, we show increased platelet response in healthy subjects homozygous for Cx37-1019C compared with subjects carrying the Cx37-1019T allele. Our results suggest that Cx37 gap junction channels allow the propagation between platelets of antiaggregating signals, a mechanism that may be severely decreased in Cx37-319P platelets.
Methods

Mice
Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice were progeny of the original colony, on a C57BL/6J background. 5, 12 Genotyping was performed as described. 5, 12 Housing and animal experiments were approved by the Swiss Federal Veterinary Office.
Preparation of Murine and Human Washed Platelets
Blood was drawn from the inferior vena cava into acid-citratedextrose solution to obtain platelet-rich plasma (PRP), and washed platelets were prepared as described in the online-only Data Supplement. Washed human platelets were prepared as described. 13 
Preparation of Platelet-Rich Plasma in 96 Healthy Subjects
Ninety-six unrelated healthy men aged 18 to 40 years were recruited. 14 All subjects gave written informed consent, and the study protocol was approved by the ethics committee of University Hospitals of Geneva. PRP was prepared as described in the onlineonly Data Supplement.
Thrombopoietin-Differentiated CD34 ؉ Cells
Cord blood cells were collected after informed consent was obtained. CD34 ϩ cells were purified with a CD34 microbeads kit (Miltenyi Biotec) as described by the manufacturer and cultured with polyethylene glycol/recombinant human megakaryocyte growth and development factor. After 12 days of culture, cells derived from these cultures were used for investigations.
Isolation of Murine Bone Marrow Cells
Single-cell suspensions were obtained from bone marrow flushed from femur and tibia. Cells adherent to gelatin-coated coverslips were fixed as described below.
Western Blotting
Western blotting was performed as described. 15 Blotted proteins were then incubated overnight at 4°C with rabbit polyclonal (2 g/mL; Alpha Diagnostic International) Cx37 antibodies or anti-␤-actin (1:1000; Sigma), which was used as a loading control. Specificity of the Cx37 labeling was confirmed by preabsorption of the polyclonal antibodies for 15 minutes at room temperature with 20 g/mL cognate immunogenic peptide (Alpha Diagnostic International).
Immunofluorescence
Cells were fixed in ice-cold methanol and immunolabeled with rabbit Cx37 antibodies. One antibody, used for the experiments shown in Figure 1C and 1D and Figure II in the online-only Data Supplement, was purchased from Alpha Diagnostic International. A second antibody together with its preimmune serum was kindly provided to us by Dr Daniel Gros (IBDM-LGPD, Marseille, France) and was used in the experiment in Figure I 
Platelet Adhesion
Adhesion to immobilized fibrinogen or collagen was quantified as described. 16 
Bleeding Time
A stopwatch was started immediately on tail transection to determine time to cessation of bleeding.
Thrombosis Models
Intravital microscopy was performed on mouse mesenteric arteries. Platelets were labeled directly in vivo by the injection of rhodamine 6G. After selection of the studied field, vessel wall injury was generated by a filter paper saturated with a 20% FeCl 3 solution. Time to vessel wall occlusion was measured, as determined by cessation of the blood cell flow. Thromboembolism was performed as described. 16
Vasomotor Responses
Rings of descending thoracic aortas with intact endothelium were suspended in a multichannel myograph. They were progressively stretched to a passive tension of 5 mN that gives the optimal length-tension relationship. Contractility with KCl and phenylephrine was measured. Then aortic rings were precontracted with phenylephrine to match the level of precontraction. Subsequent relaxations with acetylcholine or sodium nitroprusside were measured. Two aortic rings per mouse were used, and results were averaged.
Murine Platelet Aggregation
Platelet aggregation was performed as described. 16 When indicated, Cx37 ϩ/ϩ washed platelets were preincubated with 200 mol/L Cx37 mimetic peptides 5 before stimulation (2 to 5 minutes). Platelet aggregation was measured turbidimetrically with the use of an optical Platelet Aggregation Profiler (model PAP-4, Bio/Data).
Human Platelet Aggregation
Washed Platelets
The platelet suspension was incubated with either vehicle or ␣-glycyrrhetinic acid (␣-GA) before stimulation with the following agonists: arachidonic acid (AA), ADP, TRAP-6 peptide, or collagen.
Platelet-Rich Plasma
Platelet aggregation in PRP was performed with the use of the following agonists: AA, collagen, or ADP.
Fluorescein Isothiocyanate/Phalloidin Staining
Washed platelets were placed on coverslips coated with fibrinogen or collagen. Nonadherent platelets were washed away, and adherent cells were fixed and permeabilized in 0.1% Triton X-100 and incubated in fluorescein isothiocyanate/phalloidin for 15 minutes.
Evaluation of Gap Junctional Intercellular Communication
GJIC within platelet aggregates and in Cx37-expressing HeLa cells was evaluated by intracellular microinjection of neurobiotin. HeLa cells were transfected with a pIRES2-eGFP vector containing Cx37-1019C or Cx37-1019T cDNA. 17 Neurobiotin was detected by incubating the fixed platelet aggregate or HeLa cells with streptavidin-rhodamine.
Statistical Analyses
Data are shown as meanϮSEM. 
Results
Cx37 Is Expressed by Platelets and Megakaryocytes
To test for the presence of connexins in platelets, we performed Western blots on total protein obtained from resting and activated human platelets. As shown in Figure  1A , both resting and activated human platelets showed a band at a molecular weight (Ϸ37 kDa) similar to the one observed in mouse ECs, our positive control. This 37-kDa band disappeared on preincubation of the antibody with its immunogenic peptide, indicating the specificity of the reaction ( Figure 1B) . In contrast, we did not detect other vascular connexins (ie, Cx43 and Cx40) in human platelets (data not shown). Cx37 was also detected by immunofluorescence on the surface of isolated human ( Figure I in the online-only Data Supplement) and murine ( Figure 1C ) adherent platelets. As expected, no staining was detected in human platelets with the use of preimmune serum ( Figure I in the online-only Data Supplement) and in platelets obtained from Cx37 Ϫ/Ϫ mice ( Figure 1C ). Finally, confocal microscopy of immunostained murine platelet aggregates revealed Cx37 staining at areas of cell-to-cell contact between platelets ( Figure 1D and Figure II in the online-only Data Supplement). We also studied Cx37 expression in megakaryocytes. Cx37 was detected in murine megakaryocytes with a recrudescence of Cx37 expression in forming pseudopods ( Figure 2A ). Finally, Cx37 expression was confirmed in thrombopoietindifferentiated human CD34 ϩ cells by Western blot ( Figure  2B ). Thus, Cx37 is expressed by murine and human platelets and by murine megakaryocytes and thrombopoietindifferentiated human CD34 ϩ cells.
Cx37 Deficiency in Mice Shortens Bleeding Time
Cx37 Ϫ/Ϫ mice did not suffer spontaneous bleeding or thrombosis. Bleeding time was measured after tail transection of Cx37 Ϫ/Ϫ and Cx37 ϩ/ϩ mice. We obtained significant differences in the cessation of bleeding: Bleeding time was on average shortened by Ͼ50% in Cx37 Ϫ/Ϫ mice (nϭ20 per group; PϽ0.01) ( Figure 3A ). Thus, Cx37 deficiency in mice shortens bleeding time.
Cx37 Deficiency in Mice Increases Thrombus Propensity
We used different thrombosis models to determine the effects of Cx37 deficiency. In the first model, thrombus formation was recorded by intravital microscopy, and we measured the time to form an occlusive thrombus in FeCl 3 -injured mesenteric arteries. In Cx37 ϩ/ϩ mice, thrombi grew to occlusive size in 50 minutes, and half of the vessels did not occlude by 60 minutes after injury, when observation was terminated. In Cx37 Ϫ/Ϫ mice, thrombi grew to occlusive size in 20 minutes, and all injured arteries were occluded ( Figure 3B ). Although emboli generated during thrombus formation were rare events in Cx37 ϩ/ϩ mice, they were never observed in Cx37 Ϫ/Ϫ mice.
Bleeding time and thrombus formation after arterial injury depend on multiple factors, including vasoconstriction and platelet response. Because Cx37 is highly expressed in ECs and in some types of vascular smooth muscle cells, we compared vasomotor responses in aortic rings of Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice. Although maximal tension in response to 1 mol/L phenylephrine was increased in Cx37 Ϫ/Ϫ mice (Cx37 Ϫ/Ϫ : 11.4Ϯ0.7 mN and Cx37 ϩ/ϩ : 6.0Ϯ1.2 mN; nϭ4 per group; PϽ0.0075), no difference in sensitivity to the compound was observed between Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice ( Figure 4A ). This suggests that a variance in intrinsic contractile properties between Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice might result in a stronger vasoconstriction in Cx37 Ϫ/Ϫ mice. We did not observe, however, a difference in maximal tension with 100 mmol/L KCl (Cx37 Ϫ/Ϫ : 11.0Ϯ1.2 mN and Cx37 ϩ/ϩ : 7.6Ϯ1.7 mN; nϭ4 per group; Pϭ0.1965). Importantly, endothelium-dependent (acetylcholine) and -independent (sodium nitroprusside) relaxations were not different between the 2 groups of mice ( Figure 4B and 4C). To exclude a contribution of vasoconstriction in thrombus formation, we next induced thromboembolism by intravenous injection of collagen and epinephrine in anesthetized mice. In this model, thrombus formation is recognized to be platelet dependent. Cx37 ϩ/ϩ mice survived 4.2Ϯ0.4 minutes compared with Cx37 Ϫ/Ϫ mice that died at 1.9Ϯ0.3 minutes (meanϮSEM; nϭ8 per group; PϽ0.001; Figure 5 ). These data indicate that thrombus forms more rapidly and extensively in Cx37 Ϫ/Ϫ than in Cx37 ϩ/ϩ mice. Altogether, these experiments point to a major role of platelet Cx37 in thrombus formation, although Cx37 in vascular wall smooth muscle cells may play an additional role in specific cases in which vasoconstriction occurs.
Cx37 Deficiency in Mice Increases Platelet Aggregation
The prothrombotic mechanisms of Cx37 deficiency were further studied by analyzing platelet function in Cx37 Ϫ/Ϫ mice. Cx37 Ϫ/Ϫ mice had a normal platelet count and morphology (data not shown). However, platelet aggregation studies revealed significant functional differences between Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice. Platelet aggregation was increased in Cx37 Ϫ/Ϫ mice compared with Cx37 ϩ/ϩ in response to AA ( Figure 6A ), ADP ( Figure 6B ), thrombin ( Figure 6C ), and collagen ( Figure 6D ). At a suboptimal concentration of ADP (2 mol/L), the extent of aggregation was increased by Ϸ50% in the Cx37 Ϫ/Ϫ platelets (representative tracing in Figure 2 . Megakaryocytes express connexin 37 (Cx37). A, Cx37 is expressed in murine megakaryocytes with recrudescence of expression at the extremity of forming pseudopods. Photographs are combinations of fluorescent signal with transmitted light to localize cells, and nucleus is counterstained with DAPI (multiple slices of 0.32 m; barϭ20 m). B, Cx37 expression by Western blotting of total proteins (50 g) from thrombopoietin (TPO)-differentiated human CD34 ϩ cells (TPO-CD34 ϩ cells). CD34 ϩ cells were cultured for 12 days in Iscove's modified Dulbecco medium supplemented with polyethylene glycol/ recombinant human megakaryocyte growth and development factor at a final concentration of 10 ng/mL. Ten micrograms of total proteins from untransfected HeLa cells (HeLa wild-type [WT]) or transfected HeLa cells expressing Cx37-319S (HeLa Cx37-S) or Cx37-319P (HeLa Cx37-P) was used as negative and positive control, respectively. ␤-Actin was used as loading control. Figure 6B ; Cx37 ϩ/ϩ mice: 16.2Ϯ0.2% and Cx37 Ϫ/Ϫ mice: 36.0Ϯ0.3%; meanϮSEM; nϭ4 per group; PϽ0.05). Aggregation in response to higher concentrations (5 and 10 mol/L) was comparable in Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice (data not shown). Aggregation in response to low (1 and 2 g/mL) and high (10 g/mL) concentrations of collagen did not differ between Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ platelets (data not shown). However, the extent of aggregation in response to 5 g/mL collagen was increased in average by Ϸ50% in the Cx37 Ϫ/Ϫ platelets (representative tracing in Figure 6D ; Cx37 ϩ/ϩ mice: 23.5Ϯ5.3% and Cx37 Ϫ/Ϫ mice: 48.7Ϯ2.7%; meanϮSEM; nϭ4 per group; PϽ0.05).
Increase in the extent of platelet aggregation was reproduced when murine Cx37 ϩ/ϩ platelets were pretreated with 200 mol/L Cx37 mimetic peptides 5 and then stimulated by either 5 mol/L ADP ( Figure 6E ) or 5 g/mL collagen ( Figure 6F ). Platelet adhesion to either immobilized fibrinogen (200 g/mL) or collagen (50 g/mL) was comparable in both genotypes when platelets were plated at a concentration of 120 G/L ( Figure 6G ). However, when Cx37 Ϫ/Ϫ platelets were plated at a higher concentration (250 G/L), they formed stable aggregates after 1 hour of incubation that were not washed out by 2 thorough washings with buffer. In contrast, Cx37 ϩ/ϩ platelet aggregates, when plated at the same concentration, were washed out, and only a dense platelet monolayer remained on immobilized fibrinogen or collagen ( Figure 6H ). These data indicate that Cx37 deficiency in mice increases platelet aggregation but not platelet adhesion to either immobilized fibrinogen or collagen under static conditions.
Blocking Cx37 Channels Increases Aggregation of Human Platelets
The role of Cx37 in platelet function was further studied in human platelets. Washed platelets from 6 healthy volunteers were incubated 5 minutes with either 20 or 40 mol/L of the gap junction blocker ␣-GA or vehicle before a suboptimal concentration of AA (37.5 mol/L), ADP (5 mol/L), TRAP-6 (0.25 mol/L), or collagen (0.5 g/mL) was added. Maximal aggregation responses were recorded for each agonist used, and results are depicted in Figure 7 . There was a graded amplification of the aggregation profile along with ␣-GA concentrations. Interestingly, the aggregation response in platelets from 2 to 3 volunteers showed a stronger reaction to connexin inhibition. Moreover, the collagen lag time (ie, the interval between collagen addition and the onset of aggregation) decreased from a median value of Ͼ200 seconds after incubation with vehicle to 76 and 60 seconds after incubation with 20 and 40 mol/L ␣-GA, respectively (PϽ0.01). These observations in humans corroborate data in mice, confirming the involvement of Cx37 channels in limiting platelet aggregation.
Platelets Are Functionally Coupled During Aggregation
We next studied whether platelets formed functional gap junction channels during aggregation. To this end, platelets activated with thrombin (1 IU/mL) in a plate coated with immobilized fibrinogen (200 g/mL) were microinjected with the Cx37-permeable tracer neurobiotin within an aggregate (encircled in Figure 8A , top left). The tracer was allowed to diffuse to neighboring platelets for 3 minutes, and then aggregates were fixed and subjected to immunolabeling to detect neurobiotin. As illustrated in Figure 8A (top), we observed extensive diffusion of neurobiotin in 3 of 4 injections in human platelet aggregates. The diffusion of neurobiotin was inhibited in platelets exposed to a gap junction blocker ( Figure  8A , top right: presence of gap junction blocker, carbenoxolone 50 mol/L; nϭ3). To confirm these results, we repeated the experiments in aggregating platelets from Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice. We detected spreading of the tracer into neighboring Cx37 ϩ/ϩ platelets in 4 of 6 aggregates ( Figure 8A, bottom left) . In contrast, neurobiotin transfer was not observed between Cx37 Ϫ/Ϫ platelets ( Figure 8A, bottom right; nϭ4) . These results support the view that Cx37 forms functional gap junction channels during platelet aggregation.
Cx37-319S-Expressing Cells Display Larger Channel Permeability
The human Cx37 gene exhibits a single nucleotide polymorphism resulting in a nonconservative amino acid change in the regulatory C-terminus of the Cx37 protein (P319S). To evaluate the consequence of this polymorphism on GJIC, we transfected Cx37-1019C or Cx37-1019T cDNA into communication-deficient HeLa cells. Clones with equal Cx37 expression level at the cell membrane were selected 17 and injected with neurobiotin. As illustrated in Figure 8B and 8C, we observed extensive diffusion of neurobiotin in HeLa cells expressing Cx37-319S (nϭ9). In contrast, the diffusion of the tracer was markedly decreased (PϽ0.01) in HeLa cells expressing Cx37-319P (nϭ9). These results indicate a significant difference in the permeability of Cx37 polymorphic channels.
Platelet Aggregation Response in Humans Is Associated With the Cx37-C1019T Polymorphism
To investigate whether the Cx37 single nucleotide polymorphism may also be associated with platelet reactivity, we genotyped 96 healthy male subjects of Caucasian descent participating in a platelet function study. 14 The respective frequencies of the 1019C and 1019T alleles were 66% and 34% and were in Hardy-Weinberg equilibrium. Platelet aggregation was evaluated in citrated PRP. As shown in the Table, there was a graded and significant increase in aggregation response with various agonists, except with AA and 20 mol/L ADP, according to the number of 1019C alleles. There was, however, an obvious trend with the use of AA. Similar to platelet aggregation response in Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ mice, aggregation of human platelet with a high concentration of ADP (20 mol/L) did not differ across the genotype. Of note, we did not adjust for multiple tests on these correlated aggregation responses, and the error rate may be inflated as a consequence. Multivariable logistic regression analysis with independent variable coded 0 and 1 for values under and above the median, respectively, indicated that the association of C1019T polymorphism and maximal platelet aggregation response to 2 mol/L ADP and 5 mol/L ADP remained significant after adjustment for platelet count, hematocrit, plasma fibrinogen, and von Willebrand ristocetin cofactor assay. Within the limitation imposed by our population size, our study indicates that the Cx37 single nucleotide polymorphism may constitute a marker for platelet reactivity. These observations are consistent with the hypothesis that an antiaggregating signal may spread more efficiently between platelets through Cx37-319S gap junction channels, which in turn results in decreased platelet reactivity.
Discussion
Platelets are brought into close proximity at the site of vascular injury. Contacts that develop between nearby platelets allow interactions to occur among molecules on the surface of adjacent platelets. The various molecules involved in this process (reviewed in Brass et al 18 ) include either receptors (␣ IIb ␤ 3 , Tyro3 family members, Eph kinases, SLAM), adhesion molecules (platelet/endothelial cell adhesion molecule-1 and thymocyte marker of the Xenopus or CTX family members such as junctional adhesion molecule-A, EC-selective adhesion molecule, CD226), or soluble molecules populating the gaps between platelets (thromboxane A 2 , ADP, Gas6, soluble CD40L, Sema4D). Signaling through SLAM-SLAM or ephrin-Eph kinases, interactions are dependent on or facilitated by contacts occurring between platelets during aggregation. 19 -21 Gas6 is secreted by activated platelets and can bind to its receptors Tyro3, Axl, and Mer to modulate ␣ IIb ␤ 3 outside-in signaling. 16, 22 Soluble CD40L 23 or Sema4D 24 is shed from the platelet membrane surface on activation and can selectively activate platelets through ␣ IIb ␤ 3 outside-in signaling. 23, 24 The importance of such signaling molecules in the perpetuation phase of platelet aggregation has been well documented with the use of in vitro studies or in vivo models of thrombus formation in genetically engineered mice. We report here for the first time that human and murine platelets as well as megakaryocytes express the gap junction protein Cx37. Several proteins of tight junctions were previously identified on platelets such as junctional adhesion molecule-A, junctional adhesion molecule-C, and ECselective adhesion molecule (reviewed in Brass et al 18 ). Interestingly, we show that mice deficient in Cx37 exhibit a shorter bleeding time and an increase in thrombus propensity and stability in 2 different thrombosis models. In addition, exposure of murine and human platelets to gap junction blockers increased their aggregation in response to multiple agonists. However, platelet adhesion to either immobilized fibrinogen or collagen was not influenced by Cx37 deficiency at low platelet concentration, indicating that contact between platelets is necessary for the expression of the phenotype; the participation of contacts between platelets and ECs and/or leukocytes was not excluded. Altogether, our data suggest that Cx37, like platelet/endothelial cell adhesion molecule-1 [25] [26] [27] or EC-selective adhesion molecule, 28 for example, plays a restraining role on thrombus propensity.
Gap junction channels are made by the docking of 2 halves, each half being located at the membrane of apposing cells. They consist of connexin hexamers, a structure referred to as connexons or hemichannels, which by themselves may provide a mean for transplasmalemmal communication. 29 Among these connexins, 3 are known to be expressed in the vascular wall, namely, Cx37, Cx40, and Cx43. 30 -33 Cx37 is also expressed on monocytes and macrophages. 5, 34 In monocytes, ATP release through Cx37 hemichannels decreased their adhesion to the substrate. 5 In contrast, ADP release in platelets has been shown to stimulate calcium signaling, thereby promoting platelet adhesion and aggregation. 35 In our study, platelet adhesion to immobilized fibrinogen and collagen was performed in static conditions, and we did not find any differences between Cx37 ϩ/ϩ and Cx37 Ϫ/Ϫ platelets when plated at low concentrations at which they were unable to form gap junctions. In contrast, when platelets were plated at high concentrations, we observed functional gap junctions between aggregating Cx37 ϩ/ϩ but not Cx37 Ϫ/Ϫ platelets. In addition, this GJIC was abolished in murine and human platelets exposed to a gap junction inhibitor. Thus, the data presented here, in which not only Cx37-deficient mice but also pharmacological blockers and blocking peptides were used, strongly indicate that functional gap junctions rather than signaling through hemichannels or interaction of Cx37 with extracellular substances are directly involved in the antiaggregating effect of Cx37.
The importance of functional gap junction channels between platelets is further supported by the association of a known polymorphism in the human Cx37 gene and platelet aggregation responses. We found that healthy subjects homozygous for Cx37-1019C, coding for Cx37-319P, display an increased platelet response compared with subjects carrying the Cx37-1019T allele, coding for Cx37-319S. Interestingly, we report here that Cx37-319S gap junction channels are more permeable to neurobiotin than Cx37-319P channels. These observations led us to propose that antiaggregating signals diffuse more efficiently through Cx37-319S gap junction channels to decrease platelet reactivity. cAMP inhibits platelets by activating protein kinase A, which in turn phosphorylates several intracellular substrates, resulting in the inhibition of multiple platelet functions, such as cytoskeletal reorganization, integrin activation, and secretion. 36 -38 In vitro studies performed with the use of flow chambers show that elevation of cAMP inhibits platelet adhesion to immobilized von Willebrand factor 39 and collagen. 40 In vivo, it has been demonstrated that initial accumulation of platelets during thrombus formation is inhibited by elevation of basal cAMP levels. 41 The movement of cAMP through gap junction channels was demonstrated nearly 30 years ago. 42, 43 It is also interesting to note that cell-to-cell transfer of cAMP through Cx37 gap junction channels is thought to regulate several physiological processes. For example, female Cx37 Ϫ/Ϫ mice display infertility. 12 These mice lack mature Graaf follicles, fail to ovulate, and develop numerous inappropriate corpora lutea. Interestingly, Cx37 participates in the gap junctions between the oocyte and the granulosa cells of the follicle. 44 Selective assembly of Cx37 into heterocellular gap junctions at the oocyte/granulosa cell interface 44 and follicular gap junctions are known to play a crucial role in the maintenance of meiotic arrest of the oocyte in a follicle via low tonic amounts of cAMP signaling from the granulosa to the oocyte. [45] [46] [47] [48] Similar to the follicle, it is possible that Cx37 gap junction channels support the intercellular spread of antiaggregating signals like cAMP between platelets, thereby limiting exaggerated accumulation of platelets and propensity of the aggregate. The identity of the antiaggregating signals in platelets remains, however, to be determined. Recently, an antiadhesion signal for leukocytes has been reported to diffuse through endothelial gap junction channels made of Cx40. 49 However, it cannot be ruled out that loss of connectivity between Cx37-deficient platelets may enhance the intracellular concentration of proaggregating signals in the newly recruited platelets at the edge of the Data presented are number of healthy subjects (n) and median maximal platelet aggregation response (first-to-third quartile) after addition of arachidonic acid (AA), ADP, or collagen. The nonparametric Cuzick test was used to calculate trend across all 3 genotypes (CC, CT, and TT).
aggregate (for example, induced by activation of P2Y12/ADP receptor).
To date, several gene polymorphism association studies have detected a link between the C1019T Cx37 polymorphism and coronary artery disease as well as myocardial infarction in various populations. Surprisingly, the published association studies appear contradictory. Whereas stenosis in coronary arteries seems to be associated with 1019C, coding for Cx37-319P, 9, 10 increased risk for myocardial infarction appeared to be associated with 1019T coding for Cx37-319S. 6, 7 In a previous study, we demonstrated that Cx37-319S-expressing monocytes display increased adherence to the endothelium, likely resulting in excessive monocyte recruitment and vulnerable atherosclerotic lesions. 5 Because the mechanism explaining the association between Cx37-319P and increased risk of arterial stenosis has not yet been clarified, it would be of particular interest to examine the role of platelets in this process as well. The generation of knock-in mice for either Cx37 polymorph may help to resolve this issue. It is noteworthy that platelets have been shown to be involved in restenosis after stent implantation, 50 and 2 haplotypes of the platelet ADP receptor P2Y12 gene were shown recently to be associated with restenosis. 51 Altogether, our data show that Cx37, by establishing gap junctional communication between aggregating platelets, limits thrombus propensity. We propose that transfer between platelets of an antiaggregating factor occurs after thrombus formation has begun following agonist stimulation. It is likely that the putative antiaggregating factor intersects with intracellular signaling pathways rather than by changing the sensitivity of the agonists' receptors. In this respect, gap junctional communication between aggregating platelets should thus be considered a fine-tuner of the normal response. Although Cx37 in vascular smooth muscle cells may play an additional role in the in vivo experiments in which vasoconstriction occurs, data obtained on platelet aggregation ex vivo evidenced differences according to the genotype in both murine and human platelets. These findings should open new avenues for the development of antiplatelet drugs that target thrombus propensity.
